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Background: Since 2000, systemic thrombolysis has been the only approved curative and causal treatment for
acute ischemic stroke. In 2009, the guidelines of the German Society for Neurology were updated and the
therapeutic window for performing thrombolysis was extended. The implementation of new therapies is influenced
by many factors. We analyzed the factors at the organizational level that influence the implementation of
thrombolysis in stroke patients.
Methods: The data published by the majority of German hospitals in their structured quality reports was assessed.
We calculated a regression model in order to measure the influence of hospital/department-level characteristics
(e.g., teaching status, ownership, location, and number of hospital beds) on the implementation of thrombolysis in
2006 (this is the earliest point in time that can be analyzed on this data basis). In order to measure the effect of the
guideline update in 2009 on the thrombolysis rate (TR) change between 2008 and 2010, we performed a Wilcoxon
signed-rank test and utilized a regression model.
Results: In 2006, 61.5% of a total of 286 neurology departments performed systemic thrombolysis to treat ischemic
strokes. The influencing factors for the use of systemic thrombolysis in 2006 were the existence of a stroke unit (+)
and a hospital size of between 500 and 1,000 beds (−). A significant increase of the mean departmental TR
(thrombolysis rate) from 6.7% to 9.2% between 2008 and 2010 was observed after the guideline update in 2009. For
the departments performing thrombolysis in 2008 and 2010, our analysis could not show any additional influencing
factors on a structural level that would explain the TR rise during the period 2008–2010.
Conclusions: Because ischemic stroke patients benefit from systemic thrombolysis, it is necessary to examine
possible barriers at the organizational level that hinder the implementation. Our data shows that, organizational
factors have an influence on the implementation of thrombolysis. However, the recent guideline update resulted in
a TR rise that occurred at all hospitals, regardless of the measured structural conditions, as our analysis could not
identify any structural factors that might have influenced the TR after the guideline update.
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Strokes are the most frequent cause of death worldwide,
after ischemic heart diseases [1]. Over the last decade, the
global burden of stroke, measured by disability-adjusted
life years (DALYs) has increased, with stroke being the
third leading cause of health loss [2]. With about 243,000
hospitalizations in 2010, acute stroke is one of the most
common diseases in Germany [3]. The incidence of stroke
in Germany is similar to the incidence in the US and the
other EU5 countries [4]. To date, systemic thrombolysis
with recombinant tissue plasminogen activator (rtPA, alte-
plase) constitutes the only approved curative and causal
therapy for treating acute ischemic stroke patients [5].
The most promising alternative approach is endovascular
thrombectomy. Thus far, however, trials performed have
failed to demonstrate equivalent or superior therapeutic
results [6-8]. Therefore, even if intra-arterial treatment is
considered, systemic thrombolysis should still be per-
formed as a first-line treatment in all suitable patients, as
systemic thrombolysis remains the only evidence-based
therapeutic option for patients reaching a hospital within
the therapeutic window [9]. RtPA was licensed for the
treatment of acute ischemic stroke in Germany in 2000,
4 years after its approval by the US Food and Drug Ad-
ministration (FDA) [10] and 2 years before the European
Union granted a license in 2002 [11]. With this first ap-
proval, the use of rtPA was restricted to a limited time
frame of 3 h after symptom onset. On the basis of subse-
quent studies [12,13], the guidelines of the German Soci-
ety for Neurology [11], as well as several other national
and international guidelines, were updated in 2009. The
recommended therapeutic window for performing sys-
temic thrombolysis was then extended from 3 to 4.5 h
[14-16]. Because of this increased time window, more
acute ischemic stroke patients should be able to receive
systemic thrombolysis [17], and as a result, the thromboly-
sis rate (percentage of patients receiving thrombolysis,
TR) would be expected to rise.
The function of a guideline is to provide recommenda-
tions for the optimal treatment scheme and to set treat-
ment standards. Recommendations are based on the
latest study results and are therefore evidence-based.
Nevertheless, only a small percentage of these guidelines
are implemented into clinical routines [18,19]. Especially
with regard to the treatment of acute events like ische-
mic stroke, evidence-based guidelines, though widely
disseminated, are poorly adhered to [20,21]. Nevertheless,
a guideline promoting a new medical treatment regime
represents an innovation that should be incorporated into
a care provider’s actions and a hospital’s daily routines
as quickly as possible. The implementation process
starts with the decision to implement the therapeutic
innovation, followed by its routine use [22]. The deci-
sion can be made by a senior organizational manager(in terms of organizational issues) or by the medical de-
partment heads where medical innovations are involved.
There are, however, many factors that influence the
successful implementation of evidence-based health inno-
vations. According to the conceptual framework used by
Chaudoir et al., there are five different levels (the struc-
tural, organizational, patient, provider, and innovation
levels) that influence the implementation outcome [23].
Hospital characteristics on the organizational-structural
level—for example, teaching status, ownership, hospital
size—have been found to have an impact on adherence to
recommended care processes and evidence-based guide-
lines [24-26]. Another factor on the structural level that
was found to have an influence on a hospital’s perform-
ance with respect to guideline-congruent treatment is the
hospital’s location (rural vs. urban) [27,28]. For the imple-
mentation of clinical guidelines for the treatment of acute
ischemic stroke patients, qualitative studies show that a
health professional’s adherence to clinical guidelines is—at
least to a great extent—influenced by the organizational-
structural level [29,30]. Regarding the influence of teach-
ing status on the performance of thrombolysis, a study
from the Netherlands found that systemic thrombolysis
was utilized far more often in an academic setting [30]. In
addition, non-university hospitals in Sweden took 2–3
years longer to implement thrombolysis, with such hospi-
tals not recording thrombolysis rates similar to university
hospitals until 2008 [31]. With regard to a hospital’s lo-
cation, rural hospitals in Australia seem to have the
same thrombolysis rate as hospitals located in metropol-
itan regions [32].
A comparison of countries shows that the TR ranges
from 1.4% in the UK (2008) [33] to 5% (2009) in the US
[34], with 64% of US hospitals not applying any thromb-
olysis (2007) [35]. In 2010, the thrombolysis rate in
Germany was 8.9% [3], whereby 38% of hospitals that
treated ischemic stroke patients did not perform sys-
temic thrombolysis [36]. Since systemic thrombolysis is
the only approved curative and causal therapy for treat-
ing patients with an acute ischemic stroke, it is import-
ant to know what enables or prevents hospitals from
implementing this therapy into their clinical routines.
Thus, the aim of this study was to identify factors at the
organizational level that facilitate early implementation
of guidelines for treating acute ischemic stroke patients.
The definition of ‘early implementation’ is based on the
works of Rogers [37]. Because the implementation of a
new technology occurs in different phases, the adoption
of an innovation can be differentiated by its timing.
Our study aims to answer the following question:
which factors at the organizational level—such as
teaching status, experience in treating ischemic stroke
patients, and ownership—have an impact upon a hospital
department’s decision to implement systemic thrombolysis
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In addition to analyzing systemic thrombolysis implemen-
tation and the treatment situation of acute ischemic stroke
patients in 2006, we explored whether the guideline up-
date in 2009 led to changes in clinical routines, and we
also examined which organizational issues influenced this
process.
Methods
Our study is based on data provided by German hospi-
tals in their structured quality reports, which all German
hospitals have been required to publish since 2005. The
content and structure are determined by the Federal
Joint Committee (G-BA) in Germany. The structured
quality reports are published every 2 years and include
structural as well as process data. All main diagnoses
(ICD codes) and performed procedures are reported for
each hospital department. The data provided can be
used to develop a comprehensive picture of the health-
care provision in Germany. Our analyses are based on
data published in 2006, as this is the earliest possible
data available. However, we also used data from 2008
and 2010. We included all hospitals that published a
structured quality report and treated ischemic stroke pa-
tients (main diagnosis ICD code GM: I63) in a neurology
department. The performance of thrombolysis and the
existence of a stroke unit (i.e., a unit specialized in the
treatment of acute stroke patients) were identified on
the basis of documented Operationen- und Prozedur-
enschlüssel (OPS) codes, which are a national classifica-
tion of health interventions in Germany, analogous to
the International Classification of Procedures in Medi-
cine (ICPM) defined by WHO. According to the OPS
codes version 2006–2010, a systemic thrombolysis has
the OPS code 8-020.8. Because there is no specification
for the specific indication, we restricted our analysis to
neurology departments in order to exclude the possible
inclusion of thrombolysis due to an indication other
than acute ischemic stroke (e.g., myocardial infarction or
thromboembolic event). Given the fact that almost 70%
of all ischemic stroke patients were treated by a neur-
ology department in Germany in 2010 [36], the restric-
tion of our study to neurology departments limits the
number of analyzed ischemic stroke cases. Nevertheless,
our analysis still accounts for the majority of stroke
patients.
Along with the OPS code for systemic thrombolysis,
we also identified the documented OPS codes 8-981 and
8-98b. These define departments as being specialized in
the treatment of acute stroke patients (stroke unit). The
requirements for the use of the codes are the existence
of a specialized team for treating acute stroke as well as
the utilization of monitoring devices, the existence of a
facility for computer tomography imaging, and structuralconditions that allow for the performance of systemic
thrombolysis. The thrombolysis rate (TR) was calculated
by dividing the number of coded systemic thrombolysis
procedures by the number of coded ischemic stroke pa-
tients per year. For the year 2006, it was possible to
analyze data from 286 different neurology departments
that treated more than 113,700 ischemic stroke patients.
To evaluate the influence of the guideline update in
2009, we measured the thrombolysis rate change be-
tween 2008 and 2010. To this end, the data from 367 de-
partments in 2008 was matched with the data published
by the hospitals for the year 2010. As a matching vari-
able, we used the institutional code, an unambiguous
identification number, and the hospital’s postal code.
Hospitals that could not be matched by postal code and
institutional code were matched by their name and pos-
tal code. Of the 367 hospitals that treated ischemic
stroke patients in a neurology department in 2008, 348
could be matched. Overall, 19 hospitals in 2008 and 29
hospitals in 2010 that treated ischemic stroke patients
could not be matched by this procedure.
According to Lehrman et al., organizational character-
istics influence a hospital’s clinical processes and mea-
sures of care [25]. For this reason, we included hospital
organizational and departmental-level parameters in our
study. On the hospital level, these parameters are owner-
ship, hospital size (measured by the total number of
beds), teaching status, and location. A hospital’s location
is defined by its urbanization grade in accordance with
the definition of the German Federal Statistics Bureau
(i.e., urban, semi-urban, and rural). We therefore matched
the hospital data with a list of municipalities from the year
2010 (as published by the Federal Statistics Bureau). As
an explanatory variable at the departmental level, we in-
cluded in the models the existence of a stroke unit as
defined by the OPS codes 8-981 and 8-98b as well as
the number of treated ischemic stroke patients.
To identify possible organizational factors influencing
the performance of systemic thrombolysis on acute is-
chemic stroke patients, we calculated a multiple logistic
regression model for the year 2006. The dependent vari-
able here was the performance of systemic thrombolysis
as early as 2006, categorized as a dichotomous variable
with the specification ‘performance of systemic thromb-
olysis: “yes” or “no”. Explanatory variables were ownership,
number of beds, teaching status, existence of a stroke unit,
and the number of treated ischemic stroke patients. The
logistic regression analysis was based on 280 neurology
departments, as six hospitals were excluded from this ana-
lysis because of a lack of data related to ownership.
The Wilcoxon signed-rank test was performed to com-
pare the thrombolysis rate in 2008 and 2010 in order to
examine the rate before and after the guideline update
in 2009.
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determine whether there were factors at the organizational
level that enabled hospital departments to implement the
guideline update in 2009. The dependent variable was the
systemic TR change between 2008 and 2010, measured as
the difference between the TR in 2008 and 2010 for all
hospitals that performed thrombolysis in 2008. As with
aggregated data, the depth of implementation cannot be
measured directly; the TR change functions as a surrogate
indicator. As explanatory variables, parameters on the
hospital and department level (i.e., ownership, number of
beds, location, degree of urbanization, teaching status, ex-
istence of a stroke unit, and the number of treated ische-
mic stroke patients) were included in Model 1. In Model
2, we took the TR in 2008 into account in order to adjust
for the depth of implementation that had already been
achieved.
Data analysis and statistical calculations were performed
using STATA 12.
Results
The number of ischemic stroke patients treated by a neur-
ology department increased from approximately 113,700
in 2006 to around 144,000 in 2008 but then decreased
to roughly 136,800 in 2010. The percentage of ischemic
stroke patients receiving thrombolysis in a neurology
department continuously increased from approximately
4.8% in 2006 to approximately 11.0% in 2010 (mean de-
partmental thrombolysis rates: approximately 4.6% and
9.2%, respectively) (Figure 1). With 61.5% of neurology
departments (176 out of 286) performing thrombolysis
in 2006, we can see that the majority were able to offer
a guideline-congruent therapy. However, there were also
a significant number of departments that did not imple-
ment this therapeutic option into their treatment rou-
tine. In 2010, the share of neurology departments that
treated acute ischemic stroke patients and also per-
formed thrombolysis increased to 77.5%.
In 2006, 61.5% of the neurology departments coded
the utilization of systemic thrombolysis. We calculated aFigure 1 Ischemic stroke patients treated in a neurology
department with and without thrombolysis.multiple logistic model to determine whether hospital/
department characteristics influenced a neurology de-
partment’s implementation of the guideline, and of the
only approved curative and causal therapy (i.e., systemic
thrombolysis), as early as 2006. The logistic regression
model (Table 1) shows the positive influence of the exist-
ence of a stroke unit. For the hospital’s size, measured
by the number of hospital beds, we found a negative ef-
fect for hospitals with between 500 and 1,000 beds.
None of the other variables displayed any significant
relationships.
After matching the data from 2008 and 2010, we found
that 7.8% of the neurology departments that did not per-
form thrombolysis in 2008 did treat ischemic stroke pa-
tients with systemic thrombolysis in 2010. Overall, 51.1%
of the neurology departments increased their thrombolysis
rate between 2008 and 2010. By contrast, 22.4% of the
neurology departments decreased their thrombolysis rate,
and 18.4% of the neurology departments did not perform
systemic thrombolysis in acute ischemic stroke patients ei-
ther in 2008 or in 2010.
A thrombolysis-rate ranging from 0% up to 35.7% of
ischemic stroke patients in 2010 constitutes a substantial
variation between neurology departments (Figure 2).
Each line represents one neurology department. Changes
in the thrombolysis rate are illustrated by the spikes
grounding on the red line, showing upward (TR up) or
downward (TR down) movements. The Wilcoxon
signed-rank test showed a significant increase (2.5%) in
the thrombolysis rate between 2008 and 2010.
Calculating a linear regression model on the TR
change between 2008 and 2010, we did not find any sig-
nificant factors at the organizational level that might
have influenced the TR change. (Table 2—Model 1). The
purpose of adding the 2008 TR into the model was to
measure the effect that the depth of implementation
already achieved had on the TR change after the guide-
line update in 2009 (Table 2—Model 2). The level of the
thrombolysis rate in 2008 had a significant influence on
the TR change between 2008 and 2010. For example, we
were able to show that a high TR in 2008 was associated
with a TR decrease in 2010. This effect was significant
for TRs of over ten percentage points in 2008.
As regards the implementation of thrombolysis as a
treatment for acute ischemic stroke between 2008 and
2010, the measured factors on the organizational level
were not significant—apart from the fact that none of
the 27 neurology departments that began performing
systemic thrombolysis between 2008 and 2010 were lo-
cated in a rural setting.
Discussion
The implementation of systemic thrombolysis in acute
ischemic stroke care can reduce the burden of stroke
Table 1 Logistic regression model: performance of systemic thrombolysis in 2006 (thrombolysis yes or no)
Explanatory variable B (95% CI) Standard error of B p value
Constant −0.142 (−1.838 to 1.354) 0.763 0.853
Ownership (ref. public)
Private non-profit −0.737 (−1.508 to 0.034) 0.394 0.061
Private −0.750 (−1.683 to 0.182) 0.476 0.115
Location (ref. urban)
Semi-urban −0.387 (−1.224 to 0.449) 0.427 0.364
Rural −0.904 (−2.154 to 0.346) 0.638 0.156
Teaching status (ref. teaching hospital)
University hospital 0.671 (−0.179 to 1.521) 0.434 0.122
Non-teaching hospital −0.165 (−2.203 to 1.872) 1.039 0.874
Stroke unit (ref. No)
Yes 2.876 (2.167 to 3.585) 0.362 0.000
Number of beds (ref. <100)
100–199 −0.528 (−2.007 to 0.952) 0.755 0.485
200–499 −1.206 (−2.607 to 0.197) 0.715 0.092
500–999 −1.754 (−3.346 to -0.139) 0.818 0.033
>1,000 −1.810 (−3.758 to 0.138) 0.994 0.069
Number of stroke patients in 2006 0.001 (−0.000 to 0.002) 0.000 0.080
Pseudo R2 = 0.31, N = 280
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approved curative and causal treatment [5] to date,
many countries around the world still struggle with a
thrombolysis rate below the possible optimum [32,39],
as well as with the fact that hospitals do treat acute
stroke patients but not by performing systemic thromb-
olysis [35]. It is therefore necessary to identify possible
barriers on the organizational level that prevent the im-
plementation of thrombolysis in acute ischemic strokeFigure 2 Thrombolysis rates in 2010 and 2008: each line
represents one neurology department.care. Our analyses show that an increasing number of
neurology departments performed systemic thrombolysis
between 2006 and 2010.
Influencing factors in 2006
We calculated a model for 2006 in order to answer the
question as to which organizational factors influenced
the implementation of systemic thrombolysis in that
year. At the organizational level, we identified the ex-
istence of a stroke unit (+) and hospital size (between
500 and 1,000 beds) (−) as predicting factors. By con-
trast, a study from the Netherlands found that systemic
thrombolysis was used far more in an academic setting
[30]. We did not observe a difference between teaching
and non-teaching hospitals in our study, which indi-
cates that hospitals in both non-academic and aca-
demic settings will implement to a similar degree a
fundamental novel therapy, such as thrombolysis for
acute cerebral ischemia. The same applies to a hospi-
tal’s location: hospitals in urban regions were no more
likely to perform systemic thrombolysis than hospitals
in rural regions. These findings correspond with the
results from an Australian study [32]. The question as
to why hospitals with between 500 and 1,000 beds were
less likely to have implemented systemic thrombolysis
as early as 2006 needs to be addressed through further
research.
Table 2 Linear regression on the thrombolysis rate change between 2008 and 2010 for all neurology departments
performing thrombolysis
Model 1 Model 2
Explanatory variable B (95% CI) Standard
error of B
p value B (95% CI) Standard
error of B
p value
Constant 0.069 (−0.065 to 0.203) 0.068 0.312 0.0715 (−0.044 to 0.187) 0.058 0.225
Ownership (ref. public)
Private non-profit 0.004 (−0.018 to 0.025) 0.011 0.740 0.0018 (−0.017 to 0.020) 0.009 0.851
Private 0.000 (−0.024 to 0.024) 0.012 0.981 −0.0070 (−0.027 to 0.013) 0.010 0.500
Location (ref. urban)
Semi-urban 0.004 (−0.019 to 0.027) 0.011 0.731 0.0040 (−0.016 to 0.024) 0.010 0.683
Rural −0.002 (−0.035 to 0.031) 0.017 0.907 −0.0024 (−0.031 to 0.026) 0.015 0.872
Teaching status (ref. university hospital)
Teaching hospital 0.009 (−0.026 to 0.043) 0.017 0.614 −0.0102 (−0.040 to 0.020) 0.015 0.504
Non-teaching hospital 0.002 (−0.041 to 0.044) 0.021 0.938 −0.0210 (−0.055 to 0.011) 0.017 0.259
Stroke unit (ref. no stroke unit)
Stroke unit only in 2010 −0.046 (−0.139 to 0.047) 0.047 0.333 −0.0037 (−0.085 to 0.078) 0.041 0.929
Stroke unit only in 2008 −0.045 (−0.172 to 0.082) 0.064 0.486 −0.0210 (−0.132 to 0.090) 0.056 0.709
Stroke unit in 2008 and 2010 −0.029 (−0.110 to 0.052) 0.041 0.477 −0.0001 (−0.070 to 0.070) 0.036 0.997
Number of beds (ref. <100)
100–199 −0.063 (−0.169 to 0.042) 0.054 0.239 −0.0388 (−0.130 to 0.052) 0.046 0.404
200–499 −0.027 (−0.126 to 0.071) 0.050 0.584 −0.0077 (−0.093 to 0.078) 0.043 0.858
500–999 −0.036 (−0.136 to 0.064) 0.051 0.481 −0.0130 (−0.099 to 0.074) 0.044 0.769
>1,000 −0.037 (−0.140 to 0.067) 0.053 0.487 −0.0109 (−0101 to 0.079) 0.046 0.812
Number of stroke patients in 2008 0.000 (−0.000 to 0.000) 0.000 0.096 0.000 (−0.000 to 0.000) 0.000 0.233
Thrombolysis rate 2008 (ref.: <0.5)
≥0.05 and <0.10 −0.0174 (−0.037 to 0.002) 0.010 0.076
≥0.10 and <0.20 −0.0462 (−0.065 to −0.027) 0.010 0.000
≥0.20 −0.1500 (−0.183 to −0.117) 0.017 0.000
Adj. R2 = −0.02, N = 256 Adj. R2: 0.25, N = 256
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It cannot be said whether the TR increase between 2008
and 2010 can be explained by the guideline update in
2009 (resulting in an extended time window for per-
forming systemic thrombolysis) or if it was instead part
of an ongoing process of implementing systemic
thrombolysis for the treatment of acute ischemic stroke
patients. It is noteworthy that the time frame between
the guideline update and our assessment was not very
long. However, the extension of the time window in
which thrombolysis can be performed did not constitute
a completely new approach but rather an extension of
an already established treatment modality. In Sweden,
thrombolysis within the extended time frame was imple-
mented just a few months after new recommendations
and study protocols were published [40]. The Riks-
Stroke study attributed the TR increase to the prolonged
therapeutic time interval, as the TR increase within 3 h
after the onset of symptoms had leveled off since theend of 2008 in Sweden [40]. Similar results were obtained
in the SITS-ISTR study, where a rapid implementation
process was reported, accompanied by a simultaneous in-
crease in ischemic stroke patients treated with systemic
thrombolysis within the 3-h time frame [17].
We did not find any factors at the organizational level
that influenced the TR change between 2008 and 2010.
These results are in line with the findings of the Riks-
Stroke study, which found that non-university hospitals
were just as fast as university hospitals in implementing
the new recommendations [40].
The negative influence of a high TR in 2008 on the TR
change in 2010 implies that it is difficult to continuously
maintain a very high TR. It seems that in a system where
thrombolysis is already very well established, it is not
possible for the TR to rise beyond a certain level. More-
over, even though the time window for applying thromb-
olysis has been extended, patients should nevertheless
still be treated as quickly as possible after symptom
Scholten et al. Implementation Science  (2015) 10:10 Page 7 of 9onset, as the chances of recovery decrease as the interval
between symptom onset and treatment gets longer [12].
Stroke-experienced environments with well-established
processes and short delays between symptom onset and
hospital admission are thus likely to benefit less from
the extended time window. Nevertheless, further re-
search into this issue is warranted.
The organizational level and beyond
Our analysis suggests that systemic thrombolysis was con-
tinuously implemented between 2006 and 2010. Whether
or not a neurology department performs thrombolysis is a
decision to be made by each hospital that treats ischemic
stroke patients. If one considers innovation as a continu-
ous process between non-use and committed use [22], the
thrombolysis rate would stand for the implementation
level of this innovative treatment. Increasing the TR is
a challenge that involves several levels [41]. According
to Chaudoir et al. [23], there are five different levels
(the structural, organizational, patient, provider, and
innovation levels) that influence the implementation
outcome. Our analysis is based on the structural level.
Klein and Sorra state that effective implementation is
influenced by the implementation climate and the
innovation-values fit [22]. This, in turn, is influenced
by the structural level. If the implementation climate,
which exists at the organizational level [42], plays a
significant role, should be analyzed in future research,
along with the organizational readiness to change [43].
Organizational readiness consists of the organization
members’ knowledge and willingness to make a
change, and it also includes the organizational re-
sources available to implement the change [44]. In our
study, we estimated the effects of ownership, hospital
size (number of beds), location, teaching status, exist-
ence of a stroke unit, and number of treated ischemic
stroke patients as organizational-level factors that
might potentially influence the depth of implementa-
tion of systemic thrombolysis for ischemic stroke pa-
tients. We therefore estimated the effect of hospital/
department level issues on implementation behavior
with regard to systemic thrombolysis. Our analysis
comprises only structural organizational effects. Along
with structural organizational factors that influence
the implementation routine, organizational aspects
such as leadership and social interaction have also
been identified as crucial elements in the implementa-
tion of thrombolytic therapies for acute ischemic
stroke patients [45]. Making a decision to change be-
havior and perform a guideline-congruent treatment is,
at least in part, the responsibility of individual health
professionals [46]. Here—i.e., in the realm of social
cognitive theories—there is a need for more studies
that might answer the question regarding the nature ofthe interaction between innovation implementation
and the individual level [47]. Barriers that hinder the
use of systemic thrombolysis to treat acute stroke pa-
tients can be found on both the pre-admission (in the
form of patient-related and paramedic-related barriers)
and the post-admission level [48].
Because systemic thrombolysis can only be performed
if the ischemic stroke patient arrives at the hospital
within the therapeutic time frame, action has been taken
in Germany in recent years to inform the public about
the relevant symptoms of a stroke and how important it
is to get to the hospital immediately. Although a German
study suggests that 54% of German stroke patients reach
a hospital within 3 h after symptom onset [49], the pub-
lished overall TR remained at 8.9% in 2010 [3]. This
suggest that efforts to achieve a significant improvement
in stroke treatment must also focus on hospitals and the
things that prevent the application of systemic thromb-
olysis, even if the patients arrive at the hospital within
the therapeutic time frame of 4.5 h after the onset of
symptoms. Similar results have been found for the UK,
where over 28% of acute stroke patients were present in
a hospital on time, based on a 3 h rule [33].
The international perspective
Although scientific results are distributed internationally,
new guidelines and recommendations have to be imple-
mented in each country and health-care system—and in
every hospital. Because the implementation process is in-
fluenced by many factors [23], the question also has to be
raised regarding the extent to which these factors are in-
fluenced by specific national characteristics. Several stud-
ies have shown the effect the organizational level has on
the implementation of guidelines, with similar results hav-
ing been obtained across different national settings
[24-32]. With this in mind, we focused on organizational
level parameters that can be compared on an international
scale: ownership, hospital location, hospital size, teaching
status, and the existence of a stroke unit. An international
group of researchers identified the TR as a potential perform-
ance measure for the comparison of different organizational
structures or countries, although population bias has to be
accounted for as well [50]. To reduce the population effect
to a minimum, we focused in our study on the implemen-
tation of systemic thrombolysis and on the TR change as
parameters that are generally not influenced by the patient
level. To our knowledge, this is the first study to analyze
the effect of these parameters on organizational behavior
in terms of implementing thrombolysis to treat acute
stroke patients (based on nationwide data).
Limitations
Our study has some limitations. The analysis is based on
administrative data provided by hospitals. Although all
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quality report, not all hospitals comply with this legal
obligation. According to our estimates, less than 5% of all
German hospitals do not release their data to the public.
The data basis is routinely collected for claim and admin-
istrative purposes, which explains why only documented
medical procedures are accounted for. Because we did not
have access to clinical data, our analyses were restricted to
the organizational level. We were therefore not able to
consider the patient level. Information about the patient
level is essential for comparing the TR between hospitals,
or even between countries, as an absolute measure, as
population bias resulting from national characteristics can
occur [50]. Hospital density or national stroke awareness
campaigns can have an impact on the pre-admission level,
for example. The first year data was available on the hos-
pital level in Germany was 2006. With systemic thromb-
olysis having been licensed in Germany as early as 2000,
an analysis of implementation at an earlier date would
have been preferable.
Conclusion
Who does it first? Our data suggests that the imple-
mentation of thrombolysis in the treatment regime for
acute ischemic stroke patients is mainly influenced by
the existence of a stroke unit (+), and in part, by
organizational size (−) as well. The results indicate that
teaching status, ownership, and location did not influ-
ence the implementation of systemic thrombolysis.
This result can encourage different types of hospitals
that treat ischemic stroke patients to establish stroke
units and incorporate systemic thrombolysis into their
daily routines, since according to our data and the mea-
sured characteristics, there seem to be no other structural
barriers at the organizational level. On the other hand,
further research must be done in order to gain greater
insight into the organizational climate, which influences
organizational responsiveness.
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